Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Non-Current Liabilities: 2014-2022

Historic Total Non-Current Liabilities for vTv Therapeutics (VTVT) over the last 6 years, with Mar 2022 value amounting to $13.1 million.

  • vTv Therapeutics' Total Non-Current Liabilities rose 27.19% to $13.1 million in Q1 2022 from the same period last year, while for Mar 2022 it was $13.1 million, marking a year-over-year increase of 27.19%. This contributed to the annual value of $9.0 million for FY2021, which is 17.87% down from last year.
  • According to the latest figures from Q1 2022, vTv Therapeutics' Total Non-Current Liabilities is $13.1 million, which was up 46.17% from $9.0 million recorded in Q4 2021.
  • Over the past 5 years, vTv Therapeutics' Total Non-Current Liabilities peaked at $43.2 million during Q2 2018, and registered a low of $8.3 million during Q3 2021.
  • Over the past 3 years, vTv Therapeutics' median Total Non-Current Liabilities value was $10.9 million (recorded in 2020), while the average stood at $11.9 million.
  • As far as peak fluctuations go, vTv Therapeutics' Total Non-Current Liabilities spiked by 44.95% in 2018, and later crashed by 49.82% in 2019.
  • Quarterly analysis of 5 years shows vTv Therapeutics' Total Non-Current Liabilities stood at $28.7 million in 2018, then plummeted by 37.75% to $17.8 million in 2019, then slumped by 38.66% to $10.9 million in 2020, then declined by 17.87% to $9.0 million in 2021, then increased by 27.19% to $13.1 million in 2022.
  • Its Total Non-Current Liabilities was $13.1 million in Q1 2022, compared to $9.0 million in Q4 2021 and $8.3 million in Q3 2021.